Investment opportunities now available

Opportunity to become a category leader in patient monitoring

Treating kidney disease costs over $120B a year
$2B a week spent by US Medicare alone

Value-based providers are seizing the initiative – and market share
Rapid, venture-backed growth with 10% of kidney patients now in value-based care

Improved outcomes start with a patient-centric approach
Providers & patients need better data & tools to lower health risks & enable new treatments

Download corporate summary

Download a summary here.

Request investor presentation

Backed by life sciences investors

At Kalium Health we welcome investors who share our vision of expanding patient access while driving down the cost of long-term disease management.

We partner with investors who:

Recognise the challenges and opportunities in healthcare innovation
Enjoy deep-diving into our novel, world-class technology
Are well-placed to support us through international commercialisation and rapid company growth

We benefit from strong support from our current investors including the University of Cambridge, Martlet Capital, Kidney Research UK, Jonathan Milner and experienced business angels.